Process for manipulating the level of glycan content of a glycoprotein

US10822630B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10822630-B2
Application numberUS-202016783117-A
CountryUS
Kind codeB2
Filing dateFeb 5, 2020
Priority dateDec 1, 2014
Publication dateNov 3, 2020
Grant dateNov 3, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for manipulating the fucosylated glycan content on a recombinant protein comprising inoculating a bioreactor with mammalian host cells expressing the recombinant protein, culturing the host cells in a serum free, chemically defined cell culture medium; wherein the cell culture medium includes from 10 to 100 ppb copper and from 50 to 1000 nM manganese, harvesting the recombinant protein produced by the host cell. 2. The method of claim 1 , wherein there is also an increase in the level of β-galactosylation on the recombinant protein. 3. The method according to claim 1 , wherein the concentration of copper is 100 ppb. 4. The method according to claim 1 , wherein the concentration of manganese is 1000 nM. 5. The method according to claim 1 , wherein the fucosylated glycan content is manipulated to influence the level of afucosylated and β-galactosylated glycans without impacting cell culture performance. 6. The method according to claim 1 , further comprising a temperature shift. 7. The method according to claim 6 , wherein the temperature shift is from 36° C. to 31° C. 8. The method according to claim 6 , wherein the temperature shift occurs at the transition between the growth phase and production phase. 9. The method according to claim 6 , wherein the temperature shift occurs during the production phase. 10. The method according claim 1 wherein the host cell expressing the recombinant protein is cultured in a batch culture, fed-batch culture, perfusion culture, or combinations thereof. 11. The method according to claim 10 , wherein the culture is a perfusion culture. 12. The method according to claim 11 , wherein perfusion comprises continuous perfusion. 13. The method according to claim 11 , wherein the rate of perfusion is constant. 14. The method according to claim 11 , wherein the perfusion is performed at a rate of less than or equal to 1.0 working volumes per day. 15. The method according to claim 11 , wherein the perfusion is accomplished by alternating tangential flow. 16. The method according to claim 1 , wherein the bioreactor has a capacity of at least 500 L. 17. The method according to claim 1 wherein the bioreactor has a capacity of at least 500 L to 2000 L. 18. The method according to claim 1 wherein the bioreactor has a capacity of at least 1000 L to 2000 L. 19. The method according to claim 1 , wherein the bioreactor is inoculated with at least 0.5×10 6 cells/mL. 20. The method according to claim 1 , wherein the serum-free chemically defined cell culture medium is a perfusion cell culture medium. 21. The method according to claim 1 , wherein the host cells are Chinese Hamster Ovary (CHO) cells. 22. The method according to claim 1 , wherein the recombinant protein is a glycoprotein. 23. The method according to claim 1 , wherein the recombinant protein is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a recombinant fusion protein, or a cytokine. 24. The method according to claim 1 , wherein the recombinant protein produced by the host cell is purified and formulated into a pharmaceutically acceptable formulation.

Assignees

Inventors

Classifications

  • having a known sequence of two or more amino acids, e.g. glutathione · CPC title

  • C12P21/00Primary

    Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

  • Culture process characterised by temperature · CPC title

  • Buffer, e.g. pH regulation, osmotic pressure · CPC title

  • Transition metals · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10822630B2 cover?
The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
Who is the assignee on this patent?
Amgen Inc
What technology area does this patent fall under?
Primary CPC classification C12P21/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).